AIM AIM ImmunoTech

Filed: 11 Dec 20, 8:00am






Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)

(December 8, 2020)



(Exact name of registrant as specified in its charter)


Delaware 001 - 27072 52-0845822
(state or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)


2117 SW Highway 484, Ocala FL 34473
(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (352) 448-7797



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[  ]Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company [  ]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, par value $0.001 per share AIM NYSE American







Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On December 9, 2020, our Board of Directors, at the recommendation of the Compensation Committee, with input from an independent compensation advisor, utilizing Biotech Research Triangle Executive Data of Florida and based upon our recent accomplishments, adjusted salaries effective January 1, 2021 for Peter Rodino, COO, General Counsel, and Secretary, and for Ellen Lintal, CFO. Mr. Rodino’s base annual salary will increase $25,000 to $425,000 and Ms. Lintal’s annual base salary will increase $100,000 to $350,000. Mr. Rodino and Ms. Lintal were also granted bonuses of $130,000 and $100,000, respectively, and each was awarded 10-year options to purchase 75,000 shares of the Company’s common stock.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


December 11, 2020By: /s/ Thomas K. Equels
  Thomas K. Equels, CEO